PEARLITOL® mannitol
Since the 1970's, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry.
Continuous commitment to Mannitol development to Support the growth of the Pharmaceutical Market Segments
Mannitol has a share of the most desirable qualities that formulators seek in mineral, sugar or even polymeric excipients: notably a characteristic low chemical reactivity, an extraordinarily low level of hygroscopicity making it one of the "driest" products for moisture sensitive formulation, coupled with a pleasant taste and mouthfeel.
Since the 1970’s, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry: PEARLITOL® C, SD, DC, FLASH and PF.
Company name: ROQUETTE
Website: www.roquettepharma.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
